298 related articles for article (PubMed ID: 30834835)
1. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.
de Souza MVN; Nogueira TCM
Curr Top Med Chem; 2019; 19(8):567-578. PubMed ID: 30834835
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses".
Amaral L; Viveiros M; Molnar J; Kristiansen JE
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):84-7. PubMed ID: 21548876
[TBL] [Abstract][Full Text] [Related]
3. XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?
Gillespie SH; Singh K
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):77-83. PubMed ID: 21595627
[TBL] [Abstract][Full Text] [Related]
4. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
[TBL] [Abstract][Full Text] [Related]
5. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
Rajkhowa S; Deka RC
Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
[TBL] [Abstract][Full Text] [Related]
6. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
Brouqui P; Quenard F; Drancourt M
Int J Antimicrob Agents; 2017 May; 49(5):554-557. PubMed ID: 28336312
[TBL] [Abstract][Full Text] [Related]
7. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
8. It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
Amaral L
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):76. PubMed ID: 21796848
[No Abstract] [Full Text] [Related]
9. Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A; Mondal R
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.
Silva C; Perdigão J; Jordão L; Portugal I
Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633
[TBL] [Abstract][Full Text] [Related]
11. The chemical biology of new drugs in the development for tuberculosis.
Barry CE; Blanchard JS
Curr Opin Chem Biol; 2010 Aug; 14(4):456-66. PubMed ID: 20452813
[TBL] [Abstract][Full Text] [Related]
12. Classical against molecular-genetic methods for susceptibility testing of antituberculotics.
Porvaznik I; Mokry J; Solovic I
Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study.
Gallo JF; Pinhata JMW; Simonsen V; Galesi VMN; Ferrazoli L; Oliveira RS
Clin Microbiol Infect; 2018 Aug; 24(8):889-895. PubMed ID: 29175351
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
[TBL] [Abstract][Full Text] [Related]
16. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
Martins M
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
19.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic Susceptibility Patterns of Mycobacterium tuberculosis Isolates from Guizhou Province of China Against 13 Antituberculosis Drugs.
Li N; Liao X; Chen L; Wang J; Liu M; Zhang H
Microb Drug Resist; 2015 Jun; 21(3):292-6. PubMed ID: 25599413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
